文献速递前列腺癌

穿刺活检中Gleason评分9-10前列腺腺癌的预后:一项全国性人群基础研究

Prognosis of Gleason Score 9-10 Prostatic Adenocarcinoma in Needle Biopsies: A Nationwide Population-based Study.
PubMed 文献 · Eur Urol Oncol · 2023-11-17

基于瑞典前列腺癌数据库4.0中172112例经穿刺活检诊断的前列腺癌患者,分析Gleason评分4+5、5+4和5+5的10年前列腺癌死亡风险分别为0.45、0.56和0.66,全因死亡风险分别为0.73、0.81和0.87。结论认为将Gleason评分9-10合并分组会丢失预后信息。

要点

  • Gleason评分9-10患者中,4+5、5+4、5+5分别占70%、21%、9%。
  • 10年前列腺癌死亡风险:4+5为0.45,5+4为0.56,5+5为0.66。
  • 10年全因死亡风险:4+5为0.73,5+4为0.81,5+5为0.87。

核心结论

  • 在迄今最大且最完整的队列中,将Gleason评分9-10合并分组会丢失预后信息。

研究设计与样本

  • 基于瑞典前列腺癌数据库(PCBaSe)4.0的生存分析,纳入2000-2020年报告的199620例前列腺癌患者,其中172112例经穿刺活检诊断。
  • 主要治疗分类为雄激素剥夺治疗(66%)、延迟治疗(5%)、根治性前列腺切除术(7%)或根治性放疗(21%)。

主要发现

  • 共有20419例(12%)患者Gleason评分为9-10,其中4+5、5+4和5+5分别为14333例(70%)、4223例(21%)和1863例(9%)。
  • Gleason评分4+5、5+4和5+5患者10年随访时前列腺癌死亡风险分别为0.45(CI 0.44-0.46)、0.56(0.55-0.58)和0.66(0.63-0.68)。
  • Gleason评分4+5、5+4和5+5患者10年全因死亡风险分别为0.73(CI 0.72-0.74)、0.81(0.80-0.83)和0.87(0.85-0.89)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2014, prostate cancer is reported using five-tier grouping of Gleason scores. Studies have suggested prognostic heterogeneity within the groups. OBJECTIVE: We assessed the risk of prostate cancer death for men diagnosed with Gleason scores 4 + 5, 5 + 4, and 5 + 5 on needle biopsy in a population-based cohort. DESIGN, SETTING, AND PARTICIPANTS: We used the data from Prostate Cancer data Base Sweden (PCBaSe) 4.0 for a survival analysis. Among 199 620 men reported to have prostate cancer in 2000-2020, 172 112 were diagnosed on needle biopsy. The primary treatment was classified as androgen deprivation therapy (66%), deferred treatment (5%), radical prostatectomy (7%), or radical radiotherapy (21%). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The risks of death from prostate cancer in men with Gleason score 9-10 at 5 and 10 yr were used as endpoints. Multivariable Cox regression models controlling for socioeconomic factors and primary treatment were used for time-to-event analyses of death from prostate cancer and death from any causes. RESULTS AND LIMITATIONS: A total of 20 419 (12%) men had a Gleason score of 9-10, including Gleason scores of 4 + 5, 5 + 4, and 5 + 5 in 14 333 (70%), 4223 (21%), and 1863 (9%) men, respectively. The risks of prostate cancer death for men with Gleason scores 4 + 5, 5 + 4, and 5 + 5 at 10 yr of follow-up were 0.45 (confidence interval [CI] 0.44-0.46), 0.56 (0.55-0.58), and 0.66 (0.63-0.68), respectively. The risks of death of any cause for men with Gleason scores 4 + 5, 5 + 4, and 5 + 5 at 10 yr were 0.73 (CI 0.72-0.74), 0.81 (0.80-0.83), and 0.87 (0.85-0.89), respectively. CONCLUSIONS: We demonstrate in the largest and most complete cohort analyzed to date that collapsing the Gleason scores by grouping results in loss of prognostic information in men with Gleason score 9-10 cancer. PATIENT SUMMARY: Survival of prostate cancer patients with the highest tumor grades varies depending on grade composition.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Egevad L, Micoli C, Samaratunga H, et al. Prognosis of Gleason Score 9-10 Prostatic Adenocarcinoma in Needle Biopsies: A Nationwide Population-based Study. Eur Urol Oncol. 2023. PMID: 37978024. doi:10.1016/j.euo.2023.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。